Cynaroside |
Catalog No.GN10690
One-Click Copy Product Info
|
Cynaroside is a flavonoid compound that exhibits a significant inhibition of α-glucosidase, with an IC50 value of 18.3µM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 5373-11-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cynaroside is a flavonoid compound that exhibits a significant inhibition of α-glucosidase, with an IC50 value of 18.3µM[1]. Cynaroside inhibits the activity of influenza endonuclease with an IC50 value of 32µM [2]. Cynaroside can inhibit the MET/AKT/mTOR axis by reducing the phosphorylation levels of AKT, mTOR and P70S6K. It has been widely used as an anti-cancer agent to suppress the growth of various cancer cells[3].
In vitro, Cynaroside treatment for 24 hours significantly inhibited the proliferation of U87 cells and Caco-2 cells, with IC50 values of 26.34µg/ml and 97.06µg/ml, respectively[4]. Treatment with 100μM Cynaroside for 48 hours significantly inhibited the viability of HGC27 cells, causing the cell cycle to arrest at the S phase[5]. Pre-treatment with 100μM Cynaroside for 6 hours can alleviate the H2O2-induced damage to APRE-19 cells and reduce the protein expression of caspase 3[6].
In vivo, Cynaroside treatment via intraperitoneal injection at a dose of 50mg/kg every 3 days for 18 days significantly inhibited tumor growth and reduced tumor weight in HCT116 cell-xenograft tumor mouse model[7]. Intraperitoneal injection of 10mg/kg/day dose of Cynaroside was administered daily for 8 consecutive days, which significantly ameliorated renal tubular injury and interstitial fibrosis in the unilateral ureteral obstruction mouse model, accompanied by the improved renal function[8]. For 13 consecutive days, intraperitoneal injection of 20mg/kg/day dose of Cynaroside was administered daily, which effectively improved the anxiety, despair and anhedonia-like states in mice induced by chronic unpredictable mild stress (CUMS), and reduced microglial activation in the hippocampus[9].
References:
[1] Cen C, Li J, Zhou P, et al. The effects of cynaroside on lipid metabolism and lipid-related diseases: a mechanistic overview[J]. Frontiers in Pharmacology, 2025, 16: 1648614.
[2] Zima V, Radilová K, Kožíšek M, et al. Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors[J]. European Journal of Medicinal Chemistry, 2020, 208: 112754.
[3] Bouyahya A, Taha D, Benali T, et al. Natural sources, biological effects, and pharmacological properties of cynaroside[J]. Biomedicine & Pharmacotherapy, 2023, 161: 114337.
[4] Pirvu L C, Pintilie L, Albulescu A, et al. Anti-Proliferative Potential of Cynaroside and Orientin—In Silico (DYRK2) and In Vitro (U87 and Caco-2) Studies[J]. International Journal of Molecular Sciences, 2023, 24(23): 16555.
[5] Ji J, Wang Z, Sun W, et al. Effects of cynaroside on cell proliferation, apoptosis, migration and invasion though the MET/AKT/mTOR axis in gastric cancer[J]. International journal of molecular sciences, 2021, 22(22): 12125.
[6] Yu H, Li J, Hu X, et al. Protective effects of cynaroside on oxidative stress in retinal pigment epithelial cells[J]. Journal of Biochemical and Molecular Toxicology, 2019, 33(8): e22352.
[7] Lei S, Cao W, Zeng Z, et al. Cynaroside induces G1 cell cycle arrest by downregulating cell division cycle 25A in colorectal cancer[J]. Molecules, 2024, 29(7): 1508.
[8] Yang A Y, Kim J Y, Gwon M G, et al. Protective effects and mechanisms of cynaroside on renal fibrosis in mice with unilateral ureteral obstruction[J]. Redox Report, 2025, 30(1): 2500271.
[9] Zhou Y, Huang Y, Ye W, et al. Cynaroside improved depressive-like behavior in CUMS mice by suppressing microglial inflammation and ferroptosis[J]. Biomedicine & Pharmacotherapy, 2024, 173: 116425.
| Cell experiment [1]: | |
Cell lines | HGC27 cells |
Preparation Method | The HGC27 cells were cultured in a DMEM medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, and were incubated in a humidified environment at 37°C and 5% CO2. The logarithmic phase cells were inoculated into 96-well plates (1000 cells per well), and pre-cultured for 24 hours. Then, different concentrations (0, 25, 50, 75 and 100µM) of Cynaroside were added and incubated for 48 hours. The control group was treated with DMSO. MTT (5mg/ml; 20µl per well) was added to the cells and incubated in the cell culture box for 2 hours. The absorbance of the cells at 560nm was measured. |
Reaction Conditions | 0, 25, 50, 75 and 100µM; 48h |
Applications | Cynaroside significantly inhibited the viability of HGC27 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female BALB/c nude mice |
Preparation Method | Female BALB/c nude mice, aged 4-6 weeks, were raised in a specified pathogen-free environment with a 12-hour light-dark cycle. HCT116 cells were resuspended at a density of 2×106 cells/ml, and 100μl of the cell suspension was subcutaneously injected into the right side of each mouse. On the 7th day, the tumor size was measured, and mice with a volume between 50 and 70mm3 were selected for further study. Each mouse was intraperitoneally injected with DMSO or 50mg/kg of Cynaroside every 3 days. The tumor size was calculated as (length×width2)/2. After 18 days of treatment, the mice were sacrificed, and the tumor tissues were collected for analysis. |
Dosage form | 50mg/kg; every 3 days for 18 days; i.p. |
Applications | Cynaroside treatment significantly inhibited tumor growth and reduced tumor weight in mice. |
References: | |
| Cas No. | 5373-11-5 | SDF | |
| Chemical Name | 2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one | ||
| Canonical SMILES | C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O)O | ||
| Formula | C21H20O11 | M.Wt | 448.38 |
| Solubility | DMSO : 83.33 mg/mL (185.85 mM; Need ultrasonic) | Storage | Store at 2-8°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2303 mL | 11.1513 mL | 22.3025 mL |
| 5 mM | 446.1 μL | 2.2303 mL | 4.4605 mL |
| 10 mM | 223 μL | 1.1151 mL | 2.2303 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)